<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363211">
  <stage>Registered</stage>
  <submitdate>30/10/2012</submitdate>
  <approvaldate>31/10/2012</approvaldate>
  <actrnumber>ACTRN12612001150831</actrnumber>
  <trial_identification>
    <studytitle>Treatment of borderline personality disorder with omega-3 fatty acids in combination with valproic acid.</studytitle>
    <scientifictitle>Treatment of impulsivity with omega-3 fatty acids in combination with valproic acid in a group of borderline personality disoder patients.</scientifictitle>
    <utrn>U1111-1129-0346</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Borderline personality disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Eicosapentaenoic acid (EPA; 1.2 g/day) and docosahexaenoic acid (DHA; 0.8 g/day) in combination with valproic acid (800-1300 mg/day) (plasma range: 50-100 microg/ml). All drugs are administered daily for 12 weeks as oral tablets. The dose of valproic acid will be determined by treating clinician on the basis of plasma range.</interventions>
    <comparator>Valproic acid (800-1300 mg/day) (plasma range: 50-100 microg/ml). The dose of valproic acid will be determined by treating clinician on the basis of plasma range.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Global symptomatology assesed with the Clinical Global Impression Scale, item Severity (CGI-S)</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Borderline personality disorder psychopatology measured by Borderline Personality Disorder Severity Index (BPDSI)</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Impulsivity measured with Barratt Impulsiveness Scale, version 11 (BIS-11)</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Aggression and hostility measured with Modified Overt Aggression Scale (MOAS)</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Affective symptoms evaluated with the Hamilton Rating Scales for Depression and Anxiety (HAM-D, HAM-A),</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Self harm beaviour assessed with Self Harm Inventory (SHI)</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient functioning measured with Social Occupational Functioning Assessment Scale (SOFAS)</outcome>
      <timepoint>At baseline (T0) and after 4 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with a diagnosis of borderline personality disorder</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Dementia, delirium and other cognitive disorders; schizophrenia and other psychotic disorders. Lifetime bipolar disorders. Concurrent major depressive episode. Substance abuse in the last two months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/11/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, Italy</primarysponsorname>
    <primarysponsoraddress>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, via Cherasco 11, 10126, Turin, Italy</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, Italy</fundingname>
      <fundingaddress>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, via Cherasco 11, 10126, Turin, Italy</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>On the basis of research background, we will perform a RCT in order to assess efficacy and tolerability of omega-3 fatty acids in combination with valproic acid in a group of BPD patients. We will recruit consecutive outpatients with a DSM-IV-TR diagnosis of borderline personality disorder (BPD), who will be randomly assigned to two treatment arms for twelve weeks: (1) valproic acid (800-1300 mg/day) (plasma range: 50-100 microg/ml), (2) EPA (1.2 g/day) and DHA (0.8 g/day) in combination with the same dose of valproic acid. Patients will be assessed with the Clinical Global Impression Scale, item Severity (CGI-S), the Hamilton Rating Scales For Depression and Anxiety (HAM-D, HAM-A), the Social Occupational Functioning Assessment Scale (SOFAS), the BPD Severity Index (BPDSI), the Barratt Impulsiveness Scale, version 11 (BIS-11), the Modified Overt Aggression Scale (MOAS), and the Self Harm Inventory (SHI). Adverse effects will be evaluated with the Dosage Record and Treatment Emergent Symptom Scale (DOTES).</summary>
    <trialwebsite />
    <publication>Bellino S, Bozzatello P, Brignolo E, Brunetti C, Bogetto F. Omega-3 fatty acids supplementation in psychiatric disorders: a systematic review,.
Curr Psychopharmacol, 2012, 1, 353-364.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comitato Etico interaziendale A.O.U. SAN GIOVANNI BATTISTA DI TORINO, A.O. C.T.O./ MARIA ADELAIDE DI TORINO</ethicname>
      <ethicaddress>Corso Bramante 88/90 10126, Turin, Italy</ethicaddress>
      <ethicapprovaldate>23/10/2012</ethicapprovaldate>
      <hrec>0045016</hrec>
      <ethicsubmitdate>19/09/2012</ethicsubmitdate>
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Silvio Bellino</name>
      <address>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, via Cherasco 11, 10126, Turin, Italy</address>
      <phone>0039-011-6634848</phone>
      <fax>0039-011-673473</fax>
      <email>silvio.bellino@unito.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Silvio Bellino</name>
      <address>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, via Cherasco 11, 10126, Turin, Italy</address>
      <phone>0039-011-6634848</phone>
      <fax>0039-011-673473</fax>
      <email>silvio.bellino@unito.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Silvio Bellino</name>
      <address>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, via Cherasco 11, 10126, Turin, Italy</address>
      <phone>0039-011-6634848</phone>
      <fax>0039-011-673473</fax>
      <email>silvio.bellino@unito.it</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>